



## Molbio Diagnostics

### Company Information

Incorporated in October 2000, Molbio Diagnostics Limited is a global point-of-care (POC) molecular diagnostics company engaged in the research, development, manufacturing, and commercialization of rapid diagnostic solutions for infectious and non-communicable diseases. The company has developed its proprietary 'Truenat' platform, a portable, battery-operated PCR-based molecular diagnostics system designed for resource-limited settings, offering accurate test results within an hour. Molbio offers molecular testing solutions for over 30 diseases through 43 diagnostic assays, including tuberculosis (TB), COVID-19, HIV, Hepatitis B & C, and HPV. The company also provides radiology, digital pathology, and breast health screening solutions through its subsidiaries and strategic collaborations, while continuously expanding its diagnostics product pipeline through strong in-house R&D capabilities. The company operates six manufacturing facilities across India and serves customers in over 90 countries, including government health programs, diagnostic laboratories, hospitals, and international healthcare organizations. Backed by a strong portfolio of patents, global certifications, and strategic acquisitions, Molbio has established itself as a leading innovator in molecular diagnostics. As of March 31, 2026, the company employed 1,225 permanent employees across research & development, manufacturing, quality assurance, sales, finance, and corporate functions.

### Strengths

- Proprietary Truenat platform with WHO-endorsed TB molecular diagnostic technology.
- Strong R&D capabilities supported by an extensive global patent portfolio.
- Scalable business model with recurring revenues from diagnostic test kits.
- Global presence across 90+ countries with strong government and institutional customer base.
- Strategic acquisitions and collaborations expanding healthcare diagnostics portfolio.
- Experienced management team with deep expertise in molecular diagnostics and healthcare innovation.

| IPO DETAILS      |                      | TENTATIVE DATE            |                        |
|------------------|----------------------|---------------------------|------------------------|
| Opening Date     | Mon, Aug 10, 2026    | Allotment                 | Thu, Aug 13, 2026      |
| Closing Date     | Wed, Aug 12, 2026    | Initiation of Refunds     | Fri, Aug 14, 2026      |
| Price Band       | ₹768 to ₹807         | Credit of Shares to Demat | Fri, Aug 14, 2026      |
| Bid Lot          | 18 Shares            | Tentative Listing Date    | Mon, Aug 17, 2026      |
| Face Value       | ₹ 1 per share        | Cut-off time for UPI      | Aug 12, 2026 – 5 PM    |
| Total Issue Size | (agg. up to ₹940 Cr) | Registrar                 | Kfin Technologies Ltd. |

### IPO RETAIL PAYMENT CHART

| Lots | No. of Shares | Cut off price per share | Total Amount (Rs.) |
|------|---------------|-------------------------|--------------------|
| 1    | 18            | 807                     | 14526              |
| 2    | 36            | 807                     | 29052              |
| 3    | 54            | 807                     | 43578              |
| 4    | 72            | 807                     | 58104              |
| 5    | 90            | 807                     | 72630              |
| 6    | 108           | 807                     | 87156              |
| 7    | 126           | 807                     | 101682             |
| 8    | 144           | 807                     | 116208             |
| 9    | 162           | 807                     | 130734             |
| 10   | 180           | 807                     | 145260             |
| 11   | 198           | 807                     | 159786             |
| 12   | 216           | 807                     | 174312             |
| 13   | 234           | 807                     | 188838             |

**Disclaimer:** The above information is extracted from the DRHP, which is displayed on SEBI site. It is not a Invitation / advice to subscribe/ buy/ sell any securities. Prospective investors are advised to make their own assessment before taking any decision.